CE1 A Modeled Health Outcomes Evaluation of Darolutamide Plus Androgen Deprivation Therapy for High-Risk NON-Metastatic Castration-Resistant Prostate Cancer in China
Novel antiandrogens have demonstrated clinical benefit for patients with non-metastatic castration resistant prostate cancer (nmCRPC). We modeled the incremental life-years and QALYs of darolutamide+ADT compared to apalutamide+ADT and enzalutamide+ADT, for high-risk nmCRPC, in a Chinese setting.
Source: Value in Health - Category: International Medicine & Public Health Authors: J. Ming, Y. Liu, W. Lu, Y. Wu, W. Li, R. Han, S. Hu Tags: Comparative Effectiveness Studies Source Type: research
More News: Cancer | Cancer & Oncology | China Health | International Medicine & Public Health | Prostate Cancer | Study